December 2023 in “Portuguese journal of dermatology and venereology” Trichoscopy can reliably distinguish between alopecia areata and trichotillomania.
June 2024 in “Australasian Journal of Dermatology” Tofacitinib is safe and effective for treating moderate-to-severe alopecia areata.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.
139 citations
,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
1 citations
,
May 2023 in “The Journal of Dermatology” Allergen-specific immunotherapy can significantly improve hair loss and dermatitis symptoms in severe cases.
Baricitinib is more effective than methotrexate for severe alopecia areata.
December 2023 in “Journal of Cosmetic Dermatology” Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
October 2023 in “International journal of rheumatic diseases” New treatments targeting the JAK signaling pathway, especially JAK inhibitors, show promise for alopecia areata.
June 2025 in “British Journal of Dermatology” Dual-targeting therapies like Janus kinase inhibitors may treat both alopecia areata and other immune diseases.
April 2024 in “Clinical and experimental dermatology” Tofacitinib is effective for severe alopecia areata, similar to oral betamethasone.
1 citations
,
December 2025 in “Journal of the American Academy of Dermatology”
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
5 citations
,
January 2022 in “Dermatology Reports” Tofacitinib treatment for hair loss may worsen acne.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
4 citations
,
May 2019 in “Journal of The European Academy of Dermatology and Venereology” Hair loss treatment caused more hair loss in a man.
9 citations
,
October 2021 in “International Journal of Dermatology” Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.
April 2026 in “Meditsinskiy sovet = Medical Council” Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
December 2023 in “International Journal of Dermatology” Accurate diagnosis of alopecia areata incognito requires trichoscopy and histopathology.
1 citations
,
September 2023 in “Dermatology and Therapy” Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.
November 2024 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib effectively reduces severe hair loss in alopecia areata over 24 months.
October 2023 in “Regular and Young Investigator Award Abstracts” Baricitinib treatment helped reduce hair loss symptoms in mice by decreasing inflammation-related immune cells.
13 citations
,
March 2008 in “Journal of the European Academy of Dermatology and Venereology” Triamcinolone acetonide therapy for hair loss may cause a skin condition called linear lichen planus.
40 citations
,
August 2022 in “Frontiers in immunology” Blocking JAK/STAT pathways can help treat hair loss from alopecia areata.
July 2025 in “Anais Brasileiros de Dermatologia” The Brazilian version of the Alopecia Areata Quality of Life Index is reliable for assessing patients' quality of life.
April 2018 in “Journal of Investigative Dermatology” People with alopecia areata have higher levels of a heart disease marker in their blood.
1 citations
,
July 2019 in “Medicina Clínica (English Edition)” Tofacitinib partially improved hair regrowth in a patient with severe hair loss.
February 2023 in “Al-Azhar International Medical Journal /Al-Azhar International Medical Journal” Microneedling with triamcinolone is a safe, effective, and less painful treatment for alopecia areata.
January 2026 in “Experimental Dermatology” Skin-resident memory T cells may contribute to chronic alopecia areata and baricitinib could be a potential treatment.
6 citations
,
May 2023 in “Dermatology Research and Practice” IL-15 and TNF-α levels are higher in alopecia areata patients, especially in alopecia totalis.